Basal cell carcinoma Pipeline Insight
resforApril 27, 2021
The report gives a complete investigation of the Basal cell carcinoma Pipeline industry and key market improvements. The exploration record comprises of past and figure showcase data, prerequisite, territories of use, value strategies, and friend’s portions of the main organizations by topographical district. The Basal cell carcinoma Pipeline report separates the market size, by volume and worth, depending upon the kind of utilization and area.
Request sample copy of this report at
DelveInsights, Basal cell carcinoma – Pipeline Insight, 2021, report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Basal cell carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in
Cholangiocarcinoma Pipeline Insight: Therapeutic analysis of 70+ pipeline therapies and 70+ pharmaceutical companies
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Taiwan COVID-19 drug gets positive review, clinical trials to advance
focustaiwan.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from focustaiwan.tw Daily Mail and Mail on Sunday newspapers.
Data Demonstrate Efficacy of Silmitasertib Plus Gemcitabine and Cisplatin Combination Treatment for Cholangiocarcinoma
pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
TAIPEI and SAN DIEGO, Jan. 21, 2021 /PRNewswire/ Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that the first patient has enrolled into an investigator-initiated trial (IIT) of its investigational drug, Silmitasertib, as a treatment for hospitalized COVID-19 patients at Banner Health-University Medical Center in Phoenix, Arizona (BUMCP).
This IIT is a Phase II multi-center, open-label, randomized, controlled interventional prospective study. BUMCP intends to enroll 40 patients with severe COVID-19, where half will receive Silmitasertib for 14 days. Senhwa s Silmitasertib is an oral medication, targeting the host protein kinase CK2 (casein kinase 2), where virus mutations are unlikely to affect its anti-viral and anti-inflammatory efficacy. It is thought that Silmitasertib challenges the virus